ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Spero Therapeutics Inc

Spero Therapeutics Inc (SPRO)

1.69
0.04
(2.42%)
Closed March 02 04:00PM
1.70
0.01
(0.59%)
After Hours: 07:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.050.000.000.000.00 %00-
5.000.000.050.000.000.000.00 %00-

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.302.351.291.3250.000.00 %00-
5.002.804.000.003.400.000.00 %00-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MTCMMTec Inc
$ 2.55
(96.15%)
74.53M
CRDFCardiff Oncology Inc
$ 2.895
(64.02%)
45.14M
ADILAdial Pharmaceuticals Inc
$ 3.23
(58.33%)
78.09M
REALRealReal Inc
$ 2.775
(56.78%)
36.92M
BIVIBioVie Inc
$ 1.89
(52.42%)
92.69M
GIAGigCapital 5 Inc
$ 4.00
(-64.00%)
244.5k
ENCPEnergem Corporation
$ 3.86
(-54.32%)
256.23k
ESACESGEN Acquisition Corporation
$ 6.48
(-43.75%)
83.28k
SCLXScilex Holding Company
$ 1.33
(-41.41%)
9.28M
LVTXLAVA Therapeutics NV
$ 2.23
(-33.03%)
1.96M
JAGXJaguar Health Inc
$ 0.08815
(49.41%)
303.34M
SQQQProShares UltraPro Short QQQ
$ 10.49
(-4.55%)
169.04M
SOUNSoundHound AI Inc
$ 6.03
(-18.73%)
145.63M
AMDAdvanced Micro Devices Inc
$ 202.64
(5.25%)
103.82M
BIVIBioVie Inc
$ 1.89
(52.42%)
92.69M

SPRO Discussion

View Posts
Monksdream Monksdream 2 weeks ago
SPRO under $2
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
SPRO new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
SPRO new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
SPRO new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
SPRO under $2
πŸ‘οΈ0
Awl416 Awl416 6 months ago
News?
πŸ‘οΈ0
m0n m0n 7 months ago
$SPRO YuuuuGE FDA News

Spero Therapeutics shares were up 14% at $1.62 after the company received written agreement from the U.S. Food and
Drug Administration, under a Special Protocol Assessment, on the design and size of its pivotal Phase 3 clinical trial
of tebipenem HBr in patients with complicated urinary tract infection, including acute pyelonephritis.
πŸ‘οΈ0
81vette 81vette 11 months ago
Urinary tract infection drug,$66m reviewed up to 525m coming,royalties on sales is astronomical
πŸ‘οΈ0
81vette 81vette 11 months ago
Pfizer paid $5m of $40 and $80m total coming for license agreement,many more deals coming ,some phase 3 trials near done OMG THE BIG DEALS COMING
πŸ‘οΈ0
81vette 81vette 11 months ago
Look at the candle on this chart 6 month record high,now look back to see what happens with big vol
πŸ‘οΈ0
81vette 81vette 11 months ago
Look at the candle on this chart 6 month record high,now look back to see what happens with big vol
πŸ‘οΈ0
81vette 81vette 11 months ago
Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming
πŸ‘οΈ0
81vette 81vette 11 months ago
Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming
πŸ‘οΈ0
saigai saigai 1 year ago
ive had some strange experiences with stocks but this one has me baffled but not beaten..
πŸ‘οΈ0
saigai saigai 1 year ago
someone just unloaded a boat load and or shorted same. halfway around the cape and battered by high winds but not going anywhere. i cant
πŸ‘οΈ0
saigai saigai 1 year ago
they will short this back down to .80 at this rate . eff me
πŸ‘οΈ0
saigai saigai 1 year ago
folks keep walking away.. day after day after day.. ill be here im lashed to the mast of this bark as we get blistered around the cape
πŸ‘οΈ0
saigai saigai 1 year ago
damn heavy unloading
πŸ‘οΈ0
saigai saigai 1 year ago
big volume crashing again.. and i thought i was smart.. hahahahahastill bullish
πŸ‘οΈ0
saigai saigai 1 year ago
must be some kind of inside news. this keeps falling and i dont get it.. but too late now .. this is the hill i die on or
πŸ‘οΈ0
saigai saigai 1 year ago
a little retail short covering for the green. ill take it
πŸ‘οΈ0
saigai saigai 1 year ago
another day of heavy downside volume in the cards..not good
πŸ‘οΈ0
saigai saigai 1 year ago
shorts in control
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.
πŸ‘οΈ0
saigai saigai 1 year ago
a little run into earnings. ill hold through it and beyond
πŸ‘οΈ0
saigai saigai 1 year ago
https://finance.yahoo.com/news/spero-therapeutics-announces-closing-exclusive-130500913.html
πŸ‘οΈ0
saigai saigai 1 year ago
maybe we get some interest from this
https://finance.yahoo.com/news/spero-therapeutics-inc-spro-expected-140102871.html
πŸ‘οΈ0
saigai saigai 1 year ago
ill be here when the mkt cap is over a billion
πŸ‘οΈ0
saigai saigai 1 year ago
https://finance.yahoo.com/news/spero-therapeutics-present-data-idweek-120500461.html
πŸ‘οΈ0
saigai saigai 1 year ago
almost no pre opening trading...the waters have stilled.. it wont stay calm for long ..lets see which way it breaks
πŸ‘οΈ0
saigai saigai 1 year ago
bought more i wont be bought off with impatience
πŸ‘οΈ0
saigai saigai 1 year ago
enter the flipper
πŸ‘οΈ0
saigai saigai 1 year ago
just when you have given up hope a volume burst and a price pop
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
Macd on one month about to cross lower unless they have premarket news, many will sell premarket without news so if they have something releasing it premarket would be best for loyal shareholders who would miss out on a new release later in the session.
πŸ‘οΈ0
saigai saigai 1 year ago
ugly ugly day again....but in a sane world this is 10x the mkt cap it is today
πŸ‘οΈ0
saigai saigai 1 year ago
grinding our way to fair value.. whatever that is well north of here
πŸ‘οΈ0
saigai saigai 1 year ago
hopefully we hold these gains
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
β€œ8:05a ET 10/3/2022 - Globe Newswire
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

GlobeNewswireOctober 03, 2022
Event is taking place on Thursday, October 6th at 11:30 a.m. ET


Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School. During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.

A live Q&A session will follow the formal presentations. To register for the event, please click here.

Dr. Winthrop Biography:

Kevin L. Winthrop, MD, MPH, Professor of Public Health, Infectious Diseases, and Ophthalmology at Oregon Health and Science University, is a former staff infectious disease epidemiologist from the U.S. Centers for Disease Control and Prevention's Division of Tuberculosis Elimination. He has co-authored over 300 publications, many detailing the epidemiologic and clinical aspects of nontuberculous mycobacterial diseases, tuberculosis, and other infections associated with rheumatic diseases and biologic immunosuppressive therapies. Clinically, he provides regional consultations for mycobacterial diseases and other chronic chest infections and serves as the medical consultant to the Oregon Public Health Division's TB control program. His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials. He has served as a primary or senior investigator in many of these clinical and epidemiologic studies, and frequently collaborates with the Pulmonary Department on studies related to bronchiectasis. He founded the NTM Research Consortium and associated Clinical Trials Network which facilitate collaborative, multi-site grants and clinical trials among patients with NTM. He is a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.”
πŸ‘οΈ0
saigai saigai 1 year ago
look out above...lets go friday
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
β€œIf Spero’s license with Meiji is terminated, or if Meiji forfeits or loses its rights to develop, manufacture and commercialize tebipenem HBr and products that contain tebipenem HBr in any countries in the Meiji Territory, then GSK will have an exclusive first right to negotiate with Spero to add any such countries to the GSK Territory.
Under the terms of the License Agreement, Spero will receive an upfront payment of $66 million for GSK to secure rights to the medicine. Remaining potential payments are milestone based, and are as follows:

Event Milestone payments (up to)
Delivery of phase III programme
$150m
Total commercial milestone payments based on first sale (US/EU)
$150m
Sales milestone events

Net sales greater than $200m
$25m
Net sales greater than $300m
$25m
Net sales greater than $400m
$25m
Net sales greater than $500m
$50m
Net sales greater than $750m
$50m
Net sales greater than $1,000m
$50m
Total sales milestone payments:
$225m
Royalties
Low-single digit to low-double digit (if
sales exceed $1bn) tiered royalties
on net product sales.
Royalties are subject to reduction in the event of third-party licenses, entry of a generic product or expiration of patent and regulatory exclusivity prior to the tenth (10th) anniversary of the first commercial sale of a GSK Licensed Product in a particular country.
Spero will be responsible for the execution and costs of the follow-up Phase III clinical trial of tebipenem HBr. GSK will be responsible for the execution and costs of additional further development, including Phase III regulatory filing and commercialization activities for tebipenem HBr in the balance of the GSK Territory outside of the United States. Spero will also be responsible for providing and paying for the clinical supply of tebipenem HBr while GSK will be responsible for the costs of the commercial supply of tebipenem HBr. A joint development committee will be established between GSK and Spero to coordinate and review development activities for tebipenem HBr in the United States.”
πŸ‘οΈ0
saigai saigai 1 year ago
a few smart shorts see the writing on the wall..and nd it just takes time to consolidate through the profits through the shorting through the day flippers and the criminals..takes time
πŸ‘οΈ0
saigai saigai 1 year ago
red to green when you least expect it
πŸ‘οΈ0
SmokeSignals SmokeSignals 1 year ago
start loading for $5 imo
πŸ‘οΈ0
saigai saigai 1 year ago
they can play whatever game they are playing but they wont get one of my shares before 4 to 6 bucks..place your bets its coming
πŸ‘οΈ0
saigai saigai 1 year ago
shorts in control...profits still being withdrawn
πŸ‘οΈ0
saigai saigai 1 year ago
consolidation or chinese water torture a little of both
πŸ‘οΈ0
StockLogistics StockLogistics 1 year ago
Last time at these cash levels was December 2021 after the 66 million from GSK, how then to factor in current overall market conditions when there is an equivalent to better outlook for a company, possibly minus 50% across all companies from December β€˜21 SP to today, all things being equal. For SPRO profit outlook is actually better now than it was then imo.
πŸ‘οΈ0
Here Today Here Today 1 year ago
Yeah, DOW heading to a big recession correction if it keeps dipping lower. A lot of eyes watching the DOW and if it breaks below 29k
πŸ‘οΈ0
saigai saigai 1 year ago
another rough mkt day.. but im comfy holding this one
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com